Biotech Values

[DewDiligence]

AVIR—Vapendavir for rhinovirus fails phase-2b:

http://finance.yahoo.com/news/aviragen-therapeutics-announces-top-line-210100346.html

Aviragen Therapeutics…today announced top-line data from its Phase 2b SPIRITUS trial, a multi-center, randomized, double-blind, placebo-controlled, dose-ranging study of vapendavir in moderate to severe asthmatics with a rhinovirus (RV) infection. Vapendavir did not demonstrate a statistically significant reduction in the asthma control questionnaire-6 (ACQ-6) at day 14, the primary endpoint, for either the 264 mg or 528 mg cohorts compared to placebo.

This is AVIR’s second clinical failure in the past two weeks—the first was a phase-2 trial in RSV (#msg-128351130).

The stock appears to be halted.